FUTURE OF HEALTHCARE, DIGITAL HEALTHCARE
Medisafe | January 05, 2023
Medisafe, a digital therapeutics firm focused on medication engagement, recently introduced SaMD technology. This announcement comes months after receiving ISO 13485:2016 accreditation for medical devices and ISO 27001:2013 certification for pharmaceutical and digital health platforms. These international registrations demonstrate Medisafe's clinical management and patient engagement leadership.
With the market for disease management software growing, Medisafe's development shows that the company is committed to following the law, going above and beyond what is expected, and being at the forefront of SaMD development.
The achievements made by Medisafe in the past year to better serve patients, doctors, and pharma partners have earned the company a great deal of pride. Medisafe remarked that the most recent announcement of registering as a SaMD is not only a crucial step in the company's development, but it is also essential that it anticipate and address changing customer and industry needs, both regulated and unregulated, as leaders and innovators in digital therapeutics.
Medisafe continues to focus on non-regulated business-building solutions that exceed the needs of pharma, HUBs, providers, and patients.
Through an interoperable, individualized, and patient-centric approach to digital patient connectivity, Medisafe's end-to-end Care Connector platform enables organizations to effectively engage with patients throughout the medication journey, supporting pharma's vision for a more digitally enhanced future. More than 10 million registrants utilize and rely on Medisafe's platform and digital drug companion to manage their medications, validating the value it brings to patients.
Meanwhile, Medisafe will attend the 41st Annual J.P. Morgan Healthcare Conference, which will take place on January 9–12, 2023, in San Francisco, CA, USA.
Medisafe® is a premier personalized medication management platform that connects users to their families (and soon, their doctors) for support, encouragement, and expertise to provide customized notifications for visits and refills, prescription updates, personalized health advice, and discounts. It monitors blood pressure and glucose to show the benefits of taking drugs as prescribed. The company improves patient happiness and care by preventing inaccurate or missed dosages.
FUTURE OF HEALTHCARE, HEALTHCARE ANALYTICS
Rhythmlink | March 20, 2023
Rhythmlink International, LLC is pleased to announce an exciting new investment partnership with Graham Partners, a Pennsylvania-based private equity firm that specializes in industrial technology and advanced manufacturing businesses.
As a market leading designer and manufacturer of disposable neurodiagnostic devices and consumables, Rhythmlink has experienced significant growth since its founding in 2002, and this investment from Graham will ensure that growth continues along with the innovation and quality that Rhythmlink is known for. The investment was completed on March 15, 2023.
“We’re excited about this next phase of Rhythmlink,” said Shawn Regan, CEO and Co-Founder. “Graham is an excellent partner for us because of their experience in medical technology and healthcare, and we see this as a growth opportunity for us to continue to innovate beyond our current capabilities,” said Regan. “I’m extremely proud of how far we’ve come, and this is a chance for Rhythmlink to expand our business without sacrificing what matters to us – improving patient care in our field of neurodiagnostics.”
This new relationship with Graham follows Rhythmlink’s extremely successful partnership with New Heritage Capital, a Boston-based private equity firm that invested in Rhythmlink in 2019. Under partnership with New Heritage Rhythmlink grew rapidly, acquired Chalgren Enterprises and expanded their existing product line to include EMG and NCV diagnostic consumable devices. Joe Straczek, COO and CFO for Rhythmlink, spoke on the success of this relationship.
“Our partnership with New Heritage was extremely beneficial,” said Straczek. “With their support, both financially and strategically, we were able to realize significant growth, particularly with the acquisition of Chalgren. We are immensely grateful for their partnership and guidance over the last four years.”
Rhythmlink sells a full line of consumable neurodiagnostic devices for Critical Care, electroencephalography, intraoperative neuromonitoring, the ER and ICU, and long-term epilepsy monitoring.
Rhythmlink International is a medical device manufacturing company specializing in devices that help connect patients to machines to record or elicit physiologic information. Rhythmlink designs, manufactures and distributes a variety of medical devices for intraoperative neuromonitoring, electroencephalography, evoked potentials, polysomnography, long-term monitoring epilepsy and critical care units. Founded by neurodiagnostic technologists and engineers in 2002, Rhythmlink enhances patient care worldwide by transforming medical device technology that links patients to equipment. Rhythmlink also offers custom packaging, custom products, private labeling and contract manufacturing services.
About Graham Partners
Graham Partners is a private investment firm focused on investing in technology-driven companies that are spurring innovation in advanced manufacturing, resulting in product substitutions, raw materials conversions, and disruptions to traditional end markets. Graham Partners can offer control or minority capital solutions and typically targets companies with EBITDA up to $50 million. Since the firm's founding in 1988 by Steven Graham, Graham Partners has closed over 150 acquisitions, joint ventures, financings, and divestitures. The committed capital raised since inception through the Graham Partners funds together with Graham-led co-investments totals approximately $4.0 billion as of December 31, 2022, which differs from Graham’s Regulatory Assets Under Management of approximately $2.2 billion as of December 31, 2022. Investors include high-net-worth individuals, college and university endowments, foundations, public and private pension plans, funds-of-funds, and other institutional investors. Based in suburban Philadelphia, the firm has access to extensive operating resources and industrial expertise and is a member of The Graham Group, an alliance of independent operating Graham Partners Inc. businesses, investment firms and philanthropic entities, which all share in the common legacy of entrepreneur Donald Graham.
FUTURE OF HEALTHCARE, DIGITAL HEALTHCARE
Veradigm | February 10, 2023
On February 9, 2023, Veradigm® Inc. announced that Veradigm® FollowMyHealth (previously FollowMyHealth), a top mobile-first patient engagement platform, was recently named Most Improved Software Product by KLAS, a leading healthcare solution evaluator in its 2023 Best in KLAS report.
With a mobile-first strategy, Veradigm® FollowMyHealth helps meet patients on their terms and provides patient accessibility through an integrated patient engagement approach. A comprehensive patient care experience fosters collaborative experiences and facilitates access and convenience. In addition, the platform offers a real-time gateway throughout demographic groups and generates immediate and demonstrable value for health systems and independent practices.
With increasing healthcare utilization, Veradigm® FollowMyHealth integrates timing and technology to enhance the patient and healthcare provider's experiences. The platform presents a unified view of a patient's record by integrating agnostically across electronic health records (EHRs).
Veradigm's Vice President and General Manager of Consumer, Kim Franks, shared, "As a patient engagement leader for over ten years, Veradigm FollowMyHealth is constantly working to improve our solutions and delight both our clients and the patients that depend on us."
Kim Franks added, "This recognition by KLAS represents and rewards the focus and hard work our teams put into modernizing and improving our platform. We are proud to be able to provide options to tailor the patient experience in ways that can direct address the needs of our clients in the ever-changing landscape of healthcare."
(Source – Business Wire)
Veradigm® is a healthcare technology company founded in 2018 and based in Chicago, Illinois. By combining data-driven clinical insights with actionable tools, the company assists healthcare stakeholders in enhancing care delivery quality, efficiency, and value. It serves people across the healthcare system, including biopharma, health plans, healthcare providers, network partners, and, most importantly, patients. The Veradigm Network consists of a dynamic community of solutions and partners offering advanced insights, technology, and data-driven solutions, all of which collaborate to transform healthcare insightfully.